Int J Oncol 61: 110, 2022; DOI: 10.3892/ijo.2022.5400
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, concerning the Transwell assay experiments shown in Fig. 3G and I on p. 8, the data panel showing the result of the 'LNCaP / sh-CASCS11-1' experiment in Fig. 3G appeared to be overlapping with the 'LNCaP / Vector' experiment in Fig. 3I, even though the data were intended to have shown the results from differently performed experiments.
After having re-examined their original data, the authors have realized that Fig. 3G and I were inadvertently assembled incorrectly. The revised version of Fig. 3, showing the correct data for the 'LNCaP / Vector' experiment in Fig. 3I, is shown on on the next page. The authors are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum, and all the authors agree with its publication. Furthermore, the authors thank the interested reader for drawing this matter to their attention, and apologize to the readership for any inconvenience caused.
CASC11 promotes migration of PCa cells. (A-C) CASC11 knockdown attenuated cell migration in LNCaP cells, whereas CASC11 overexpression exerted the opposite effect. (D-F) CASC11 knockdown attenuated cell migration in 22Rv1 cells, whereas CASC11 overexpression exerted the opposite effect. (G and H) Transwell assay demonstrated that CASC11 knockdown inhibited cell migration in LNCaP and 22Rv1 cells. (I and J) Transwell assay demonstrated that CASC11 overexpression promoted cell migration in LNCaP and 22Rv1 cells. Scale bar, 100 μm. *P<0.05, **P<0.01 vs. sh-NC or vector. CASC11, cancer susceptibility candidate 11; NC, negative control; OE-CASC11, CASC11 overexpression plasmid; PCa, prostate cancer; sh, short hairpin.